Needham & Company Downgrades Spectranetics (SPNC) to Buy

August 9, 2016 7:22 AM EDT
Get Alerts SPNC Hot Sheet
Price: $23.95 +2.35%

Rating Summary:
    10 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 26 | Down: 29 | New: 38
Trade SPNC Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Needham & Company downgraded Spectranetics (NASDAQ: SPNC) from Strong Buy to Buy with a price target of $27.00 on valuation.

Analyst Mike Matson commented, "We hosted SPNC's CEO, Scott Drake, and COO, Shar Matin, for investor meetings last week. Management was upbeat about Stellarex's ability to take share in the drug-coated balloon (DCB) market and SPNC's ability to sustain strong growth in the base Vascular Intervention business and we come away feeling more positive about the prospects for both. However, we downgrade SPNC to Buy from Strong Buy given its valuation."

For an analyst ratings summary and ratings history on Spectranetics click here. For more ratings news on Spectranetics click here.

Shares of Spectranetics closed at $24.01 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Downgrades

Related Entities

Needham & Company

Add Your Comment